EUVIMEDEUVIMED entdecken
Crossref

Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B‐lineage acute lymphoblastic leukemia: A report of 1021 patients from India

Dikshat Gopal Gupta iD, Neelam Varma, Praveen Sharma, Mihai I Truica, Sarki A Abdulkadir, Parmod Singh, Man Updesh Singh Sachdeva, Shano Naseem, Mohammad Rizwan Siddiqui, Parveen Bose, Jogeshwar Binota, Pankaj Malhotra und 3 weitere

Cancer · 2023

DOI: 10.1002/cncr.34957 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Dikshat Gopal Gupta und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Pathology, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, I…. Hauptthemen laut MEDLINE: Fusion Proteins, bcr-abl, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 100 Literaturangaben. Gefördert von: Postgraduate Institute of Medical Education and Research, Chandigarh.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The published literature on hematological, clinical, flowcytometric‐immunophenotyping, and minimal residual disease outcomes of the prognostically important genetic subtypes of acute lymphoblastic leukemia (ALL) is scarce from low‐income countries. For newer classifications such as BCR::ABL1 ‐like ALLs, the scarcity of patient‐level data is even more pronounced.

Methods

The authors performed comprehensive detection of recurrent gene fusions and BCR::ABL1 ‐like ALL cases followed by immunophenotypic profiling and obtained clinical outcome parameters for a large cohort ( n = 1021) of patients from India. This cohort included a significant number of patients with BCR::ABL1 ‐like ALL subtype and other genetic subtypes of ALL.

Results

Patients with BCR::ABL1 ‐positive and BCR::ABL1 ‐like ALL were significantly older, had male preponderance, and expressed a higher white blood cell count than BCR::ABL1 ‐negative cases ( p < .05). Logistic regression modeling of B‐lineage‐ALL (B‐ALL) subtypes revealed that cluster of differentiation (CD)36 is a strong statistically significant predictive marker of BCR::ABL1 ‐like ALL ( p < .05). Furthermore, patients with BCR::ABL1 ‐like ALLs show a significantly higher frequency of CD36 expression compared to BCR::ABL1 ‐negative ALLs ( p < .05). In terms of clinical symptoms, lymphadenopathy is a strong statistically significant predictive marker in BCR::ABL1 ‐like ALLs compared to BCR::ABL1 ‐negative ALL cases ( p < .05). In terms of treatment outcomes, minimal residual disease (MRD) positivity in BCR::ABL1 ‐positive ALL cases were statistically significant ( p < .05), and BCR::ABL1 ‐like ALL cases had high MRD‐positivity as compared to BCR::ABL1 ‐negative ALL cases but did not show statistical significance.

Conclusions

The findings evince the use of novel therapies and personalized treatment regimens to improve the overall survival of the newer incorporated entities in B‐ALLs. This is the first report characterizing the hematological, clinical, flowcytometric‐immunophenotyping, and minimal residual disease outcomes of the prognostically significant subtypes of ALLs in patients from India. Plain Language Summary Characterizing the hematological, clinical, flowcytometric‐immunophenotyping, and minimal residual disease outcomes of the prognostically significant subtypes ( n = 1021) of acute lymphoblastic leukemia (ALLs) in patients from India. We have made two independent logistic regression models of cluster of differentiation (CD) markers and clinical symptoms to differentiate prognostically significant subtypes of ALLs. Logistic regression analysis of CD markers revealed CD36 as a strong predictor in BCR::ABL1 ‐like ALL cases compared to BCR::ABL1 ‐negative ALL cases. Logistic regression analysis of clinical symptoms revealed lymphadenopathy significantly predicts BCR::ABL1 ‐like ALLs ( p < .05). In terms of treatment outcomes, BCR::ABL1 ‐positive ALL had statistically significant minimal residual disease (MRD) ( p < .05), and BCR::ABL1 ‐like ALL cases had high MRD‐positivity but did not show statistical significance as compared to BCR::ABL1 ‐negative ALLs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fusion Proteins, bcr-ablPrecursor B-Cell Lymphoblastic Leukemia-LymphomaHumansMaleIndiaFemaleImmunophenotypingAdolescentAdultChildPrognosisChild, PreschoolYoung AdultMiddle AgedNeoplasm, ResidualTreatment OutcomeInfantAged

Stichwörter der Autor:innen

B-acute lymphoblastic leukemia (B-ALL)PGIMER in-house rapid and cost-effective classifier (PHi-RACE)cluster of differentiation (CD) markersflowcytometric-immunophenotyping (FCM-IP)high-risk ALLsrecurrent fusion transcripts (RGFs)

Substanzen

Fusion Proteins, bcr-abl

Autor:innen und Institutionen

  • Department of Urology and Pathology, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Department of Hematology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Anatomy, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Pediatrics, Northwestern University Feinberg School of Medicine and Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
  • Department of Clinical Hematology and Medical Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

ORCID-Profile: Dikshat Gopal Gupta

Förderung

  • Postgraduate Institute of Medical Education and Research, Chandigarh

Zitieren

APA

Gupta, D. G., Varma, N., Sharma, P., Truica, M. I., Abdulkadir, S. A., Singh, P., Singh Sachdeva, M. U., Naseem, S., Siddiqui, M. R., Bose, P., Binota, J., Malhotra, P., Khadwal, A., Trehan, A., & Varma, S. (2023). Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B‐lineage acute lymphoblastic leukemia: A report of 1021 patients from India. Cancer. https://doi.org/10.1002/cncr.34957

Vancouver

Gupta DG, Varma N, Sharma P, Truica MI, Abdulkadir SA, Singh P, et al. Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B‐lineage acute lymphoblastic leukemia: A report of 1021 patients from India. Cancer. 2023. doi:10.1002/cncr.34957

BibTeX
@article{Gupta2023,
  author = {Gupta, Dikshat Gopal and Varma, Neelam and Sharma, Praveen and Truica, Mihai I and Abdulkadir, Sarki A and Singh, Parmod and Singh Sachdeva, Man Updesh and Naseem, Shano and Siddiqui, Mohammad Rizwan and Bose, Parveen and Binota, Jogeshwar and Malhotra, Pankaj and Khadwal, Alka and Trehan, Amita and Varma, Subhash},
  title = {Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B‐lineage acute lymphoblastic leukemia: A report of 1021 patients from India},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34957}
}
Kostenlos starten →